GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, has shared the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude for HIV pre-exposure prophylaxis, PrEP. The data will be presented at IDWeek 2024, being held in Los Angeles, California from 16 – 19 October. Findings from two real-world evidence studies showed more than 99% effectiveness of CAB LA for PrEP in nearly 1,300 individuals. In the PILLAR implementation study, reductions were shown in stigma and anxiety among the 200 individuals using the long-acting injectable PrEP option.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces U.S. FDA accepted NDA for gepotidacin
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz
- GSK sues Moderna for U.S. patent infringement over COVID vaccines, Reuters says
- Bullfrog AI appoints Baldoni to Scientific Advisory Board
- GSK announces phase III trials ANCHOR-1, ACHOR-2 met primary endpoints